Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections

키워드

참고문헌 (151)

1. "Facility guidance for control of carbapenem-resistant Enterobacteiaceae (CRE): November 2015 update-CRE toolkit"[URL]
2. "Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities"[URL]
3. "National antibiotic-resistant bacteria surveillance annual Report" (2021)[URL]
4. Im J, "Characteristics of Carbapenem-resistant Enterobacteriaceae(CRE)in the Republic of Korea, 2022", Public Health Wkly Rep, 17, pp.115~127 (2024)
5. Tamma PD, "Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales(ESBL-E), carbapenem-resistant Enterobacterales(CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P. aeruginosa)", Clin Infect Dis, 72, pp.e169~e183 (2021)
6. Paul M, "European Society of Clinical Microbiology and Infectious Diseases(ESCMID)guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli(endorsed by European society of intensive care medicine)", Clin Microbiol Infect, 28, pp.521~547 (2022)
7. Guyatt GH, "Incorporating considerations of resources use into grading recommendations", BMJ, 336, pp.1170~1173 (2008)
8. Seo H, "Risk factors for mortality in patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae and Escherichia coli bacteremia", Infect Chemother, 53, pp.528~538 (2021)
9. Park JW, "Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea", Antimicrob Resist Infect Control, 8, pp.48~ (2019)
10. Yoon EJ, "Bloodstream infections and carbapenem-resistant Enterobacteriaceae in South Korea", Lancet Infect Dis, 19, pp.931~932 (2019)
11. Lou T, "Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae : a large multicentre case-control and cohort study", J Infect, 84, pp.637~647 (2022)
12. Chen L, "Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales", Antimicrob Agents Chemother, 65, pp.e0069821~ (2021)
13. Shirley M, "Ceftazidime-avibactam : a review in the treatment of serious Gram-negative bacterial Infections", Drugs, 78, pp.675~692 (2018)
14. Kim MK, "Antimicrobial resistance and molecular characteristics of carbapenem-resistant Enterobacteriaceae isolated in the Republic of Korea, 2021", Public Health Wkly Rep, 16, pp.541~559 (2023)
15. Li HH, "Evaluation of Xpert Carba-R assay for the detection of carbapenemase genes in Gram-negative bacteria", Biomed Res Int, 2021, pp.6614812~ (2021)
16. Huang YT, "Evaluating NG-Test CARBA 5 multiplex immunochromatographic and cepheid Xpert CARBA-R assays among carbapenem-resistant Enterobacterales isolates associated with bloodstream infection", Microbiol Spectr, 10, pp.e0172821~ (2022)
17. Johnston BD, "Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli Isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region", Antimicrob Agents Chemother, 64, pp.e00797-20~ (2020)
18. Sader HS, "Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations : results from the SENTRY surveillance program(2010-2013)", Diagn Microbiol Infect Dis, 83, pp.183~186 (2015)
19. Kim SY, "Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea", Diagn Microbiol Infect Dis, 76, pp.486~490 (2013)
20. Tumbarello M, "Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections", Curr Opin Infect Dis, 31, pp.566~577 (2018)
21. Falagas ME, "Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline", Curr Drug Metab, 10, pp.13~21 (2009)
22. Sbrana F, "Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit", Clin Infect Dis, 56, pp.697~700 (2013)
23. Wang J, "The efficacy and safety of tigecycline for the treatment of bloodstream infections : a systematic review and meta-analysis", Ann Clin Microbiol Antimicrob, 16, pp.24~ (2017)
24. Zha L, "Effectiveness and safety of high dose tigecycline for the treatment of severe infections : a systematic review and meta-analysis", Adv Ther, 37, pp.1049~1064 (2020)
25. Chen Z, "Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens", Medicine(Baltimore), 97, pp.e12467~ (2018)
26. De Pascale G, "High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria", Crit Care, 18, pp.R90~ (2014)
27. Hawkey PM, "Treatment of infections caused by multidrug-resistant Gram-negative bacteria : report of the British Society for Antimicrobial Chemotherapy", Healthcare Infection Society, J Antimicrob Chemother, pp.2018, 73(Suppl 3)[DOI]
28. Tamma PD, "Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales(ESBL-E), carbapenem-resistant Enterobacterales(CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P. aeruginosa)", Clin Infect Dis, 75, pp.187~212 (2022)
29. Ni W, "Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis", Medicine(Baltimore), 95, pp.e3126~ (2016)
30. Falagas ME, "Tetracyclines for multidrug-resistant Acinetobacter baumannii infections", Int J Antimicrob Agents, 45, pp.455~460 (2015)
31. Chen A, "Activity of minocycline against Klebsiella pneumoniae carbapenemase(KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline", Diagn Microbiol Infect Dis, 88, pp.365~367 (2017)
32. Doi Y, "Carbapenemase-producing Enterobacteriaceae", Semin Respir Crit Care Med, 36, pp.74~84 (2015)
33. Vasoo S, "Susceptibility testing for the polymyxins : two steps back, three steps forward?", J Clin Microbiol, 55, pp.2573~2582 (2017)
34. Chew KL, "Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae : comparison of sensititre, MicroScan, Vitek 2, and Etest with broth microdilution", J Clin Microbiol, 55, pp.2609~2616 (2017)
35. Garnacho-Montero J, "Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia(VAP)with intravenous colistin : a comparison with imipenem-susceptible VAP", Clin Infect Dis, 36, pp.1111~1118 (2003)
36. Levin AS, "Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii", Clin Infect Dis, 28, pp.1008~1011 (1999)
37. Markou N, "Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients", Crit Care, 7, pp.R78~R83 (2003)
38. Michalopoulos AS, "Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria : the renaissance of an old antibiotic", Clin Microbiol Infect, 11, pp.115~121 (2005)
39. Alraddadi BM, "Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae", BMC Infect Dis, 19, pp.772~ (2019)
40. Castón JJ, "Clinical efficacy of ceftazidime", avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients, 2017, pp.59, 118~123
41. Hakeam HA, "Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia", Int J Infect Dis, 109, pp.1~7 (2021)
42. Shields RK, "Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia", Antimicrob Agents Chemother, 61, pp.e00883-17~ (2017)
43. Tumbarello M, "Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections : a retrospective observational multicenter study", Clin Infect Dis, 73, pp.1664~1676 (2021)
44. Tumbarello M, "Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae", Clin Infect Dis, 68, pp.355~364 (2019)
45. van Duin D, "Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae", Clin Infect Dis, 66, pp.163~171 (2018)
46. Wunderink RG, "Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections : The TANGO II randomized clinical trial", Infect Dis Ther, 7, pp.439~455 (2018)
47. Motsch J, "RESTORE-IMI 1 : a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem", relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections, 2020, pp.70, 1799~1808
48. Zusman O, "Polymyxin monotherapy or in combination against carbapenem-resistant bacteria : systematic review and meta-analysis", J Antimicrob Chemother, 72, pp.29~39 (2017)
49. Sy CL, "Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms", J Microbiol Immunol Infect, 55, pp.359~386 (2022)
50. Vardakas KZ, "Intravenous colistin combination antimicrobial treatment vs. monotherapy : a systematic review and meta-analysis", Int J Antimicrob Agents, 51, pp.535~547 (2018)
51. Satlin MJ, "Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae(CRE)in the CRE epicenter of the United States", Antimicrob Agents Chemother, 61, pp.e02349-16~ (2017)
52. Tumbarello M, "Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae : importance of combination therapy", Clin Infect Dis, 55, pp.943~950 (2012)
53. Daikos GL, "Carbapenemase-producing Klebsiella pneumoniae bloodstream infections : lowering mortality by antibiotic combination schemes and the role of carbapenems", Antimicrob Agents Chemother, 58, pp.2322~2328 (2014)
54. Gutiérrez-Gutiérrez B, "Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae(INCREMENT) : a retrospective cohort study", Lancet Infect Dis, 17, pp.726~734 (2017)
55. Luterbach CL, "A systems-based analysis of mono-and combination therapy for carbapenem-resistant Klebsiella pneumoniae bloodstream infections", Antimicrob Agents Chemother, 66, pp.e0059122~ (2022)
56. Vardakas KZ, "Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections : a systematic review and meta-analysis", J Infect, 76, pp.321~327 (2018)
57. Mattoes HM, "Optimizing antimicrobial pharmacodynamics : dosage strategies for meropenem", Clin Ther, 26, pp.1187~1198 (2004)
58. Roberts JA, "Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution", J Antimicrob Chemother, 64, pp.142~150 (2009)
59. Paul M, "Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria : an open-label, randomised controlled trial", Lancet Infect Dis, 18, pp.391~400 (2018)
60. Tumbarello M, "Infections caused by KPC-producing Klebsiella pneumoniae : differences in therapy and mortality in a multicentre study", J Antimicrob Chemother, 70, pp.2133~2143 (2015)
61. Giannella M, "Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection", Int J Antimicrob Agents, 51, pp.244~248 (2018)
62. Durante-Mangoni E, "Management of carbapenem-resistant Enterobacteriaceae infections", Clin Microbiol Infect, 25, pp.943~950 (2019)
63. Tamma PD, "Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections", Clin Infect Dis, pp.ciad428~ (2023)
64. Ito R, "Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene", mBio, 8, pp.e00749-17~ (2017)
65. Huttner A, "Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women : a randomized clinical trial", JAMA, 319, pp.1781~1789 (2018)
66. Satlin MJ, "Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine", Antimicrob Agents Chemother, 55, pp.5893~5899 (2011)
67. Rodríguez-Baño J, "Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae", Clin Microbiol Rev, 31, pp.e00079-17~ (2018)
68. Rybak MJ, "Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity", Antimicrob Agents Chemother, 43, pp.1549~1555 (1999)
69. van Duin D, "Ceftazidime", avibactam and ceftolozane, β-lactamase inhibitor combinations, pp.Clin Infect Dis, 2016[DOI]
70. Panagiotakopoulou A, "Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase", Int J Antimicrob Agents, 29, pp.360~362 (2007)
71. Souli M, "Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model", J Antimicrob Chemother, 66, pp.611~617 (2011)
72. Crandon JL, "Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers", Antimicrob Agents Chemother, 57, pp.3299~3306 (2013)
73. Psichogiou M, "Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece : a prospective survey", J Antimicrob Chemother, 61, pp.59~63 (2008)
74. Chastain DB, "Rethinking urinary antibiotic breakpoints : analysis of urinary antibiotic concentrations to treat multidrug resistant organisms", BMC Res Notes, 11, pp.497~ (2018)
75. Kim Y, "Fluoroquinolone can be an effective treatment option for acute pyelonephritis when the minimum inhibitory concentration of levofloxacin for the causative Escherichia coli Is ≤16 mg", L, 2021, pp.10, 37~
76. Lee SS, "Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis", J Infect, 62, pp.159~164 (2011)
77. Kang CI, "Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections", Infect Chemother, 50, pp.67~100 (2018)
78. Elbaz M, "Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis", J Antimicrob Chemother, 75, pp.2307~2313 (2020)
79. Stankowicz MS, "Once-daily aminoglycoside dosing : an update on current literature", Am J Health Syst Pharm, 72, pp.1357~1364 (2015)
80. Goodlet KJ, "A systematic review of single-dose aminoglycoside therapy for urinary tract infection : is it time to resurrect an old strategy?", Antimicrob Agents Chemother, 63, pp.e02165-18~ (2018)
81. van den Bijllaardt W, "Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion", J Antimicrob Chemother, 73, pp.2380~2387 (2018)
82. Camarlinghi G, "Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods", Diagn Microbiol Infect Dis, 93, pp.74~76 (2019)
83. Elliott ZS, "The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates", J Clin Microbiol, 57, pp.e00634-19~ (2019)
84. Huttner A, "The pharmacokinetics of nitrofurantoin in healthy female volunteers : a randomized crossover study", J Antimicrob Chemother, 74, pp.1656~1661 (2019)
85. Tamma PD, "Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia", Clin Infect Dis, 64, pp.257~264 (2017)
86. Bulik CC, "Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods", J Clin Microbiol, 48, pp.2402~2406 (2010)
87. Yu Z, "Clinical outcomes of prolonged infusion(extended infusion or continuous infusion)versus intermittent bolus of meropenem in severe infection : a meta-analysis", PLoS One, 13, pp.e0201667~ (2018)
88. Wagenlehner FM, "Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis : RECAPTURE, a phase 3 randomized trial program", Clin Infect Dis, 63, pp.754~762 (2016)
89. Carmeli Y, "Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections(REPRISE) : a randomised, pathogen-directed, phase 3 study", Lancet Infect Dis, 16, pp.661~673 (2016)
90. Sheu CC, "Infections caused by carbapenem-resistant Enterobacteriaceae : an update on therapeutic options", Front Microbiol, 10, pp.80~ (2019)
91. Pallett A, "Complicated urinary tract infections : practical solutions for the treatment of multiresistant Gram-negative bacteria", J Antimicrob Chemother, 65(Suppl 3), pp.iii25~iii33 (2010)
92. Capone A, "High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality", Clin Microbiol Infect, 19, pp.E23~E30 (2013)
93. Matuschek E, "Antimicrobial susceptibility testing of colistin-evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp", Clin Microbiol Infect, 24, pp.865~870 (2018)
94. Kaye KS, "Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection : The TANGO I randomized clinical trial", JAMA, 319, pp.788~799 (2018)
95. Portsmouth S, "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens : a phase 2, randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 18, pp.1319~1328 (2018)
96. Sims M, "Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem", cilastatin plus relebactam with imipenem, J Antimicrob Chemother, pp.2017, 72[DOI]
97. Bassetti M, "Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria(CREDIBLE-CR) : a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial", Lancet Infect Dis, 21, pp.226~240 (2021)
98. Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children : guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
99. Yoon YK, "Korean guidelines for use of antibiotics for intra-abdominal infections in adults", Infect Chemother, 54, pp.812~853 (2022)
100. Bassetti M, "Antimicrobial resistance and treatment : an unmet clinical safety need", Expert Opin Drug Saf, 17, pp.669~680 (2018)
101. de Oliveira MS, "Treatment of KPC-producing Enterobacteriaceae : suboptimal efficacy of polymyxins", Clin Microbiol Infect, 21, pp.179~ (2015)
102. Gomez-Simmonds A, "Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections", Antimicrob Agents Chemother, 60, pp.3601~3607 (2016)
103. Lin YT, "Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli : a nationwide multicenter study in Taiwan", Open Forum Infect Dis, 6, pp.ofy336~ (2018)
104. Navarro-San Francisco C, "Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae : a major clinical challenge", Clin Microbiol Infect, 19, pp.E72~E79 (2013)
105. Agyeman AA, "A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections", Int J Antimicrob Agents, 55, pp.105833~ (2020)
106. Pfaller MA, "Surveillance of tigecycline activity tested against clinical isolates from a global(North America, Europe, Latin America and Asia-Pacific)collection(2016)", Int J Antimicrob Agents, 51, pp.848~853 (2018)
107. Eckmann C, "Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies", J Antimicrob Chemother, 68(Suppl 2), pp.ii25~ii35 (2013)
108. Abdallah M, "Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City", Antimicrob Agents Chemother, 59, pp.1802~1805 (2015)
109. Livermore DM, "In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii", Antimicrob Agents Chemother, 60, pp.3840~3844 (2016)
110. Solomkin J, "Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline(IGNITE 1)trial : a randomized clinical trial", JAMA Surg, 152, pp.224~232 (2017)
111. Solomkin JS, "IGNITE4 : Results of a Phase 3, Randomized, multicenter, prospective trial of Eravacycline vs meropenem in the treatment of complicated intraabdominal infections", Clin Infect Dis, 69, pp.921~929 (2019)
112. Van Hise N, "A real-world assessment of clinical outcomes and safety of eravacycline : a novel fluorocycline", Infect Dis Ther, 9, pp.1017~1028 (2020)
113. Alosaimy S, "Early experience with eravacycline for complicated infections", Open Forum Infect Dis, 7, pp.ofaa071~ (2020)
114. Lagacé-Wiens P, "Ceftazidime-avibactam : an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections", Core Evid, 9, pp.13~25 (2014)
115. Mazuski JE, "Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection : results from a randomized, controlled, double-blind, phase 3 program", Clin Infect Dis, 62, pp.1380~1389 (2016)
116. Tsolaki V, "Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients", Antimicrob Agents Chemother, 64, pp.e02320-19~ (2020)
117. Ackley R, "Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections", Antimicrob Agents Chemother, 64, pp.e02313-19~ (2020)
118. Lucasti C, "Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection", Antimicrob Agents Chemother, 60, pp.6234~6243 (2016)
119. Lapuebla A, "Activity of imipenem with relebactam against Gram-negative pathogens from New York city", Antimicrob Agents Chemother, 59, pp.5029~5031 (2015)
120. Lob SH, "In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015(Results from the SMART global surveillance program)", Antimicrob Agents Chemother, 61, pp.e02209-16~ (2017)
121. Canver MC, "Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae", Antimicrob Agents Chemother, 63, pp.e00672-19~ (2019)
122. Kulengowski B, "Imipenem", relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center, 2019, pp.77, ftz040~
123. Yang TY, "Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan", J Microbiol Immunol Infect, 55, pp.86~94 (2022)
124. Papp-Wallace KM, "Relebactam is a potent inhibitor of the KPC-2 β-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae", Antimicrob Agents Chemother, 62, pp.e00174-18~ (2018)
125. Karlowsky JA, "In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by Clinical Laboratories in North America and Europe in 2015-2016 : SIDERO-WT-2015", Int J Antimicrob Agents, 53, pp.456~466 (2019)
126. McCreary EK, "New perspectives on antimicrobial agents : cefiderocol", Antimicrob Agents Chemother, 65, pp.e0217120~ (2021)
127. Shaw E, "Clinical outcomes after combination treatment with ceftazidime", avibactam and aztreonam for NDM-1, CTX-M-15-producing Klebsiella pneumoniae infection, pp.J Antimicrob Chemother, 2018[DOI]
128. Hobson CA, "Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy", Antimicrob Agents Chemother, 63, pp.e02463-18~ (2019)
129. Benchetrit L, "Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime", avibactam combined with aztreonam in solid organ transplant recipients : report of two cases, 2020, pp.55, 105842~
130. Falcone M, "Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales", Clin Infect Dis, 72, pp.1871~1878 (2021)
131. Lodise TP, "Determining the optimal dosing of a novel combination regimen of ceftazidime", avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model, 2020, pp.75, 2622~2632
132. Tan X, "Therapeutic options for metallo-β-lactamase-producing Enterobacterales", Infect Drug Resist, 14, pp.125~142 (2021)
133. Kazmierczak KM, "In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase-and metallo-β-lactamase-producing isolates(SIDERO-WT-2014 Study)", Int J Antimicrob Agents, 53, pp.177~184 (2019)
134. Pfaller MA, "In vitro activity of meropenem", vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem, Int J Antimicrob Agents, pp.2018, 52[DOI]
135. Castanheira M, "Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime", avibactam, meropenem, J Antimicrob Chemother, pp.2021, 76[DOI]
136. Castanheira M, "Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U. S. hospitals during 2016 to 2018", Antimicrob Agents Chemother, 64, pp.e01951-19~ (2020)
137. Falcone M, "Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae", Clin Microbiol Infect, 22, pp.444~450 (2016)
138. Papadimitriou-Olivgeris M, "Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients : risk factors and predictors of mortality", Eur J Clin Microbiol Infect Dis, 36, pp.1125~1131 (2017)
139. Schmid A, "Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections : systematic review and meta-analysis", Sci Rep, 9, pp.15290~ (2019)
140. Giamarellou H, "Pharmacokinetic and pharmacodynamic evaluation of tigecycline", Expert Opin Drug Metab Toxicol, 7, pp.1459~1470 (2011)
141. Tsuji BT, "International Consensus Guidelines for the Optimal Use of the Polymyxins : Endorsed by the American College of Clinical Pharmacy(ACCP), European Society of Clinical Microbiology and Infectious Diseases(ESCMID), Infectious Diseases Society of America(IDSA), International Society for Anti-infective Pharmacology(ISAP), Society of Critical Care Medicine(SCCM), and Society of Infectious Diseases Pharmacists(SIDP)", Pharmacotherapy, 39, pp.10~39 (2019)
142. Zarkotou O, "Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment", Clin Microbiol Infect, 17, pp.1798~1803 (2011)
143. Katsiari M, "Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit : molecular characterisation and treatment challenges", J Glob Antimicrob Resist, 3, pp.123~127 (2015)
144. Kontopidou F, "Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece : a multi-centre study on clinical outcome and therapeutic options", Clin Microbiol Infect, 20, pp.O117~O123 (2014)
145. Machuca I, "Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance : importance of combination therapy without colistin and carbapenems", Antimicrob Agents Chemother, 61, pp.e00406-17~ (2017)
146. Qureshi ZA, "Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae : superiority of combination antimicrobial regimens", Antimicrob Agents Chemother, 56, pp.2108~2113 (2012)
147. Stein GE, "Tigecycline : an update", Diagn Microbiol Infect Dis, 75, pp.331~336 (2013)
148. Yahav D, "Efficacy and safety of tigecycline : a systematic review and meta-analysis", J Antimicrob Chemother, 66, pp.1963~1971 (2011)
149. Pascale R, "Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections", Expert Rev Anti Infect Ther, 17, pp.819~827 (2019)
150. Stone GG, "Clinical activity of ceftazidime", avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa : pooled data from the ceftazidime, J Antimicrob Chemother, pp.2018, 73[DOI]
151. Boyd SE, "Metallo-β-lactamases : structure, function, epidemiology, treatment options, and the development pipeline", Antimicrob Agents Chemother, 64, pp.e00397-20~ (2020)

관련 논문AI추천